A detailed history of Brevan Howard Capital Management LP transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Brevan Howard Capital Management LP holds 16,847 shares of SAGE stock, worth $91,647. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,847
Previous 43,416 61.2%
Holding current value
$91,647
Previous $471,000 74.31%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$7.02 - $13.08 $186,514 - $347,522
-26,569 Reduced 61.2%
16,847 $121,000
Q2 2024

Aug 14, 2024

BUY
$10.58 - $17.9 $248,788 - $420,918
23,515 Added 118.16%
43,416 $471,000
Q1 2024

May 15, 2024

SELL
$18.62 - $26.95 $25,434 - $36,813
-1,366 Reduced 6.42%
19,901 $372,000
Q4 2023

Feb 14, 2024

BUY
$17.1 - $22.26 $363,665 - $473,403
21,267 New
21,267 $460,000

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $323M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Brevan Howard Capital Management LP Portfolio

Follow Brevan Howard Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brevan Howard Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Brevan Howard Capital Management LP with notifications on news.